Heme Flashcards
Asprin
Analgesic, antipyretic, anti-inflammatory, anti-platelet
MOA: Irreversible COX 1&2 inhibitor by covalent acetylation Plts cant synth new COX Increased Bleeding time, Reduced TXA2 and PGs No effect PT and PTT
Toxicity:
Gastric ulceration, CNVIII
Chronic use -> acute renal failure, interstitial nephritis, upper GI bleed
Reye syndrome w/ virus in peds
OD -> resp alkalosis and then superimposed metabolic acidosis
ibuprofen
Analgesic MOA: reversible COX inhibitors half-life ~2h hold 1-2 days preop
Naproxen
Analgesic reversible cox inhibitor Tmax 1-2h half life 12-17h Hold several days preop
Clopidogrel
ADP receptor inhibitor
MOA:
Inhibits plt aggregation; irreversibly blocks ADP receptors
Clinical:
ACS, Coronary Stenting, prophylactic for thrombotic stroke
Tox: TTP/HUS
Prasugrel
ADP receptor inhibitor
MOA:
Inhibits plt aggregation; irreversibly blocks ADP receptors
Clinical:
ACS, Coronary Stenting, prophylactic for thrombotic stroke
Tox: TTP/HUS
Ticagrelor
ADP receptor inhibitor
MOA:
Inhibits plt aggregation; irreversibly blocks ADP receptors
Clinical:
ACS, Coronary Stenting, prophylactic for thrombotic stroke
Tox: TTP/HUS
Heparin
Anticoagulant
MOA:
cofactor for activation of antithrombin. Reduces thrombin, Factor Xa and IIa
short half life
Clinical use:
imediate anticoagulation for PE, ACS, MI DVT.
used during pregnancy (wont cross placenta)
Follow PTT
Tox:
Bleeding, thrombocytopenia(HIT)
osteoporosis, DDI,
Reversal = protamine sulfate
Enoxaparin
Anti-coagulant
LMWH
MOA:
LMWH acts more on Factor Xa are cofactor for activation of antithrombin. Reduces thrombin,
longer half life
Clinical use:
imediate anticoagulation for PE, ACS, MI DVT.
used during pregnancy (wont cross placenta)
SC administration
No lab monitoring
Not easily reversible
Tox:
Bleeding, thrombocytopenia(HIT)
osteoporosis, DDI,
Dalteparin
Anti-coagulant
LMWH
MOA:
LMWH acts more on Factor Xa are cofactor for activation of antithrombin. Reduces thrombin,
longer half life
Clinical use:
imediate anticoagulation for PE, ACS, MI DVT.
used during pregnancy (wont cross placenta)
SC administration
No lab monitoring
Not easily reversible
Tox:
Bleeding, thrombocytopenia(HIT)
osteoporosis, DDI,
Tinzaparin
Anti-coagulant
LMWH
MOA:
LMWH acts more on Factor Xa are cofactor for activation of antithrombin. Reduces thrombin,
longer half life
Clinical use:
imediate anticoagulation for PE, ACS, MI DVT.
used during pregnancy (wont cross placenta)
SC administration
No lab monitoring
Not easily reversible
Tox:
Bleeding, thrombocytopenia(HIT)
osteoporosis, DDI,
Fondaparinux
Anti-coagulant
LMWH
MOA:
LMWH acts more on Factor Xa are cofactor for activation of antithrombin. Reduces thrombin,
longer half life
Clinical use:
immediate anticoagulation for PE, ACS, MI DVT.
used during pregnancy (wont cross placenta)
SC administration
No lab monitoring
Not easily reversible
Tox:
Bleeding, thrombocytopenia(HIT)
osteoporosis, DDI,
No reversal agent!!
Protamine sulfate
basic protein binds negatively charged heparins
Heparin reversal agent
warfarin
Anticoagulant MOA: interferes w. gamma carboxylation of vit K dependent clotting factors II, VII, IX, X; proteins C&S CYP450 metabolism Extrinsic pathway Elevates PT Long half-life
Clinical:
chronic anticoagulation (STEMI, venous thromboembolism prophylaxis, A.fib.
Not used in pregnancy
Follow PT/INR
Tox:
bleeding, teratogenic, skin/tissue necrosis
Reversal:
Vitamin K, Fresh Frozen Plasma
Argatroban
Anticoagulant
Hirudin derivative (leeches) Direct thrombin inhibitor
heparin contraindications (HIT)
Bivalirudin
Anticoagulant
Hirudin derivative (leeches) Direct thrombin inhibitor
heparin contraindications (HIT)
Dabigatran
Oral anticoagulant
Direct thrombin inhibitor
IIa inhibitor
Heparin contraindications (HIT)
Rivaroxaban
Anticoagulant
MOA:
Direct factor Xa inhibitor
Clinical:
Treatment/prophylaxis of DVT/PE, Afib(stroke)
Oral
no monitoring
Tox:
bleeding
no reversal agents
Apixaban
Anticoagulant
MOA:
Direct factor Xa inhibitor
Clinical:
Treatment/prophylaxis of DVT, Afib(stroke)
Oral
no monitoring
Tox:
bleeding
no reversal agents
tPA
Thrombolytics
MOA:
directly/indirectly aid conversion of plasminogen -> plasmin; cleaves thrombin and fibrin clots
^^PT, ^^PTT
Clinical:
Early MI, early ischemic stroke, direct thrombolysis of severe PE
Tox:
bleeding
Contraindicated in actively bleeding, hx of intracranial bleed, recent surgery, known bleeding diathesis, severe HTN
Reversal:
fibrinolysis inhibitor = aminocaproic acid
FFP/cryoprecipitate to correct factor deficiences
Urokinase Plasminogen
Fibrinolytic Thrombolytics MOA: directly/indirectly aid conversion of plasminogen -> plasmin; cleaves thrombin and fibrin clots ^^PT, ^^PTT
Clinical:
Early MI, early ischemic stroke, direct thrombolysis of severe PE
Tox:
bleeding
Contraindicated in actively bleeding, hx of intracranial bleed, recent surgery, known bleeding diathesis, severe HTN
Reversal:
fibrinolysis inhibitor = aminocaproic acid
FFP/cryoprecipitate to correct factor deficiences
streptokinase
fibrinolytic Thrombolytics MOA: Binds plasminogen cleaves fibrin clots ^^PT, ^^PTT
Clinical:
Early MI, early ischemic stroke, direct thrombolysis of severe PE
Tox:
bleeding
Contraindicated in actively bleeding, hx of intracranial bleed, recent surgery, known bleeding diathesis, severe HTN
Reversal:
fibrinolysis inhibitor = aminocaproic acid
FFP/cryoprecipitate to correct factor deficiences
Herbal clotting inhibitors
eg Ginko
cyclophosphamide
Alkylating agent
Commonly used
MOA:
covalently crosslink DNA at Guanine N-7; requires hepatic bioactivation.
Clinical:
Solid tumors, leukemia, lymphomas, some brain
Tox:
myelosuppression, **hemorrhagic cystitis, partially prevented w. **mesna (binds toxic metabolites)
Cisplatin
bifunctional alkylating agent
MOA:
crosslinks DNA
Clinical:
testicular, bladder, ovary, lung carcinomas
Tox:
nephrotox, CNVIII damage
prevent nephrotox w/ amifostine (free radical scavenger) chloride diuresis
Renal insufficiency
Ondanestron
Antiemetic MOA: 5-HT3 central antagonist decreases vagal stim powerful central acting anti-emetic
Clinical:
antiemetic; post op and chemo
Tox:
Headache, constipation
Aprepitant
Antiemetic
Neurokinin 1 antagonist
CYP3A4 metabolism
Methotrexate
anti-metabolite
MOA:
folic acid analogue inhibits dihydrofolate reductase
–v dTMP –> –v DNA and –v protein synth
Leucovorin Rescue for bone marrow
Clinical:
cancers, leukemia, lymphomas, choriocarcinomas, sarcomas, Non-neoplastic: abortion, ectopic pregnancy, rheumatoid arthritis, psoriasis, IBD
TOX:
myelosuppression, reversible w/ leucovorin “rescue”
Macrovesicular fatty liver
mucositis, teratogenic
5-flurouricil
Nucleoside analogue
MOA:
pyrimidine analog, bioactivated to 5fF-dUMP, covalently complexes folic acid:
complex inhibits thymidylate synthase –>–vdTMP–>–vDNA and protein synth
Clinical:
colon cancer, pancreatic cancer, basal cell carcinoma
Tox: myelosuppression, ***leucovorin potentiates OD rescue w/ uridine photosensitivity